20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Alector Inc (NASDAQ:ALEC) is flashing some AL001 (latozinemab) Phase 2 data at an Alzheimer’s and Parkinson’s disease conference, this time in dementia with a different type of mutation: C9orf72.
- Results in this cohort also showed elevated progranulin levels in both plasma and cerebrospinal fluid while patients were on monthly treatment for a year.
- Additionally, clinical assessments showed a delay in annualized disease progression, approximately 54%.
- Related: Alector Stock Falls After Flashing 12-Month Data From Mid-Stage Trial In Frontotemporal Dementia Patients.
- Mean levels of neurofilament light chain (NfL), a marker of axonal damage, remained stable over the course of treatment in both plasma and CSF in latozinemab-treated FTD-C9orf72 patients.
- Mean levels of glial fibrillary acidic protein (GFAP), a biomarker of astrogliosis that indicates disease and/or injury to the central nervous system, decreased over 12 months in both plasma and CSF in latozinemab-treated FTD-C9orf72 patients.
- Price Action: ALEC shares are down 2.33% at $13.20 during the market session on the last check Tuesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!